Search results
Results from the WOW.Com Content Network
Specialty professional organizations recommend that people take the lowest effective PPI dose to achieve the desired therapeutic result when used to treat gastroesophageal reflux disease long-term. [ 20 ] [ 21 ] [ 22 ] In the United States, the Food and Drug Administration (FDA) has advised that over-the-counter PPIs, such as Prilosec OTC ...
Omeprazole is a proton-pump inhibitor (PPI) and its effectiveness is similar to that of other PPIs. [9] It can be taken by mouth or by injection into a vein . [ 1 ] [ 10 ] It is also available in the fixed-dose combination medication omeprazole/sodium bicarbonate as Zegerid [ 11 ] [ 12 ] and as Konvomep.
The H 2 receptor antagonists are a class of drugs used to block the action of histamine on parietal cells in the stomach, decreasing the production of acid by these cells. H 2 antagonists are used in the treatment of dyspepsia, although they have been surpassed in popularity by the more effective [1] proton pump inhibitors.
The primary medications used for GERD are proton-pump inhibitors, H 2 receptor blockers and antacids with or without alginic acid. [9] The use of acid suppression therapy is a common response to GERD symptoms and many people get more of this kind of treatment than their case merits.
A 14-day course of "quadruple therapy" with a proton pump inhibitor, bismuth, tetracycline, and metronidazole or tinidazole is a more complicated but also more effective regimen. In a 2011 randomized, controlled trial, the per protocol eradication rates were 93% with quadruple therapy and 70% with triple therapy.
Rabeprazole, sold under the brand name Aciphex, among others, is a medication that decreases stomach acid. [6] It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and excess stomach acid production such as in Zollinger–Ellison syndrome. [6]
Pantoprazole, sold under the brand name Protonix, among others, is a medication used for the treatment of stomach ulcers, short-term treatment of erosive esophagitis due to gastroesophageal reflux disease (GERD), maintenance of healing of erosive esophagitis, and pathological hypersecretory conditions including Zollinger–Ellison syndrome.
Linaprazan is an experimental drug for the treatment of gastroesophageal reflux disease (GERD). Unlike the proton-pump inhibitors (PPIs) which are typically used to treat GERD, linaprazan is a potassium-competitive acid blocker (P-CAB). [1] [2] Linaprazan was developed by AstraZeneca, but it was not successful in clinical trials. [3]